Cell and Gene Therapy Clinical Trial Services Market Report 2026

The cell and gene therapy clinical trial services market size has grown rapidly in recent years. It will grow from $4.18 billion in 2025 to $4.62 billion in 2026 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to increasing number of cell and gene therapy clinical trials, rising outsourcing to specialized cros, growing complexity of trial designs, expansion of rare disease research, increasing regulatory oversight of advanced therapies.

The cell and gene therapy clinical trial services market size is expected to see strong growth in the next few years. It will grow to $6.44 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to increasing demand for late-stage clinical trial services, rising adoption of digital trial technologies, expansion of global patient recruitment initiatives, growing focus on real-world evidence integration, increasing investments in precision clinical research. Major trends in the forecast period include increasing adoption of decentralized clinical trial models, growing use of digital patient recruitment platforms, rising integration of advanced data management systems, expansion of global trial site networks, enhanced focus on regulatory compliance and trial accuracy.

The increasing prevalence of genetic diseases is expected to drive the growth of the cell and gene therapy clinical trial services market in the coming years. Genetic diseases are disorders caused by changes in an individual’s DNA or genetic makeup. The prevalence of genetic diseases is rising due to several factors, including greater access to genetic testing, the occurrence of genetic mutations, and the commonality of consanguineous marriages. Cell and gene therapy clinical trial services respond to this rising prevalence by promoting the development of innovative treatments, personalizing therapies for individual patients, accelerating the translation of research into clinical applications, and broadening the treatment options for patients with genetic disorders. For example, in 2023, according to the National Health Service, a UK government body, sickle cell disorder (SCD) was the most common genetic condition in England, affecting approximately 17,000 people (NHSE, 2023). Hence, the increasing prevalence of genetic diseases is fueling the growth of the cell and gene therapy clinical trial services market.

Major companies operating in the cell and gene therapy clinical trial services market are concentrating on deploying advanced technology integrated with customer relationship management (CRM) systems to enhance efficiency and secure a competitive advantage. The CRM systems used by cell and gene therapy clinical trial services help streamline and coordinate interactions with trial participants, healthcare providers, and other stakeholders throughout the clinical trial process. For example, in April 2023, AmerisourceBergen Corporation, a US-based healthcare company, introduced the Cell and Gene Therapy (CGT) Integration Hub, a platform designed to enhance connectivity and simplify processes across the cell and gene therapy treatment pathway. This platform is supported by AmerisourceBergen's CRM system and seeks to optimize the path-to-care process by providing physicians and patient services teams with greater visibility across therapy development and delivery. The CGT Integration Hub, featuring capabilities such as expedited benefits investigation, real-time status tracking, and proactive alerts, aims to facilitate care coordination, reduce barriers, and improve the overall experience for patients and providers in delivering cell and gene therapies.

In January 2024, Kyowa Kirin Co. Ltd., a pharmaceutical company based in Japan, acquired Orchard Therapeutics Limited for an undisclosed sum. Through this acquisition, Kyowa Kirin intends to strengthen its focus on meeting the unmet medical needs of patients with genetic and severe diseases by utilizing Orchard's expertise in developing and commercializing gene therapies for rare conditions. Orchard Therapeutics Limited is a biotechnology company based in the UK, primarily focused on the research, development, and commercialization of gene therapies for rare diseases.

Major companies operating in the cell and gene therapy clinical trial services market are Thermo Fisher Scientific Inc., Sharp Services LLC, IQVIA, Laboratory Corporation of America Holdings, ICON plc, Syneos Health Inc., Catalent Pharma Solutions Inc., Charles River Laboratories International Inc., Parexel International Corporation, PRA Health Sciences Inc., Covance Inc., Medpace Holdings Inc., BioClinica Inc., Precision Medicine Group LLC, Worldwide Clinical Trials LLC, Clinigen Group plc, Evidera Inc., Advarra LLC, Veristat LLC, Clinipace Inc., Celonic AG, Cromsource Inc., Novotech Pty Ltd., MedSource Holdings Inc., Frontage Laboratories Inc.

North America was the largest region in the cell and gene therapy clinical trial services market in 2025. It is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy clinical trial services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell and gene therapy clinical trial services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the cell and gene therapy clinical trial services market by increasing costs of imported clinical trial supplies, cold-chain logistics equipment, data management systems, and specialized laboratory instruments. Trial sponsors in North America and Europe are most affected due to dependence on international supply chains, while Asia-Pacific faces cost pressure in trial execution and logistics. These tariffs are increasing overall trial budgets and timelines. However, they are also encouraging regional trial execution, localized supply sourcing, and investments in domestic clinical trial infrastructure.

The cell and gene therapy clinical trial services market research report is one of a series of new reports that provides cell and gene therapy clinical trial services market statistics, including cell and gene therapy clinical trial services industry global market size, regional shares, competitors with a cell and gene therapy clinical trial services market share, detailed cell and gene therapy clinical trial services market segments, market trends and opportunities, and any further data you may need to thrive in the cell and gene therapy clinical trial services industry. This cell and gene therapy clinical trial services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cell and gene therapy clinical trial services are specialized offerings provided by contract research organizations (CROs) or clinical trial management companies to support the design, execution, and oversight of clinical trials for cell and gene therapies. These services, which encompass activities such as protocol development, patient recruitment, regulatory compliance, and data management, form the foundation for the smooth progression of trials, ensuring accuracy, effectiveness, and adherence to rigorous standards.

The primary types of cell and gene therapy clinical trial services include clinical trial design and planning, supply and logistics support, regulatory affairs and compliance, data management and biostatistics, site management and monitoring, among others. Clinical trial design and planning involve developing and structuring the trial framework, determining the objectives, and outlining how the trial will be conducted. These services cover various therapy types, including gene therapy, cell therapy, and gene-modified cell therapy, which are applied across multiple indications such as oncology, hematology, metabolic disorders, infectious diseases, neurology, cardiovascular diseases, musculoskeletal disorders, and more. They are utilized by a range of end-users, including pharmaceutical and biotechnology companies, contract research organizations, academic and research institutions, and others.

The cell and gene therapy clinical trial services market includes revenues earned by providing services, such as regulatory pathways navigation, logistics management, patient retention strategy management, and biomarker analysis services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.